HALOPERIDOL showed no clear difference in leaving the study early ‐ Due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
It is very uncertain whether comparison 1: PERPHENAZINE changes acceptability of treatment ‐ leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).
Trifluoperazine showed no clear difference in leaving the study early: 1. Acceptability of treatment ‐ leaving… compared with low‐potency antipsychotic drugs (low certainty).
It is very uncertain whether horticultural therapy plus standard care changes satisfaction with treatment Leaving the study early compared with standard care alone (very low certainty).
INFORMATION AND COMMUNICATION TECHNOLOGY (ICT) FOR PROMPTING/SUPPORT… showed no clear difference in acceptability (of intervention): Leaving the studies early – any… compared with STANDARD CARE (low certainty).
It is very uncertain whether TRIFLUOPERAZINE changes leaving the study early ‐ any reason ‐ medium term Number of… compared with PLACEBO (very low certainty).
It is very uncertain whether intrapartum changes early neonatal sepsis compared with postpartum treatment (very low certainty).
An extended NVP regimen administered to infants for 6 weeks may leads to higher genotypic Resistance to NVP among Indian infants HIV‐infected in… compared with sdNVP (low certainty).
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. high dose (> 15‐35 mg/day) compared with OTHER DOSES (very low certainty).
HALOPERIDOL showed no clear difference in leaving the study early compared with PLACEBO (moderate certainty).
Sildenafil showed no clear difference in dropouts (People leaving the trial early) compared with placebo (high certainty).
Bupropion showed no clear difference in dropouts (People leaving the trial early) compared with placebo (high certainty).
It is very uncertain whether EMDR changes leaving study early for any reason compared with trauma‐focused CBT (very low certainty).
It is very uncertain whether EMDR changes leaving the study early for any reason compared with non‐TFCBT (very low certainty).
It is very uncertain whether EMDR changes leaving study early for any reason compared with other therapies (very low certainty).
It is very uncertain whether non‐TFCBT changes leaving the study early due to any reason compared with waitlist/Usual Care (very low certainty).
It is very uncertain whether group TFCBT changes leaving the study early for any reason compared with waitlist/Usual Care (very low certainty).